Sex and age differences in human platelet aggregation

Johnson, Malcolm; Ramey, Estelle R.; Ramwell, Peter W.

doi:10.1038/253355a0

Cited by 265 publications

(139 citation statements)

References 13 publications

Supporting

Mentioning

121

Contrasting

Order By: Relevance

“…A number of ex vivo functional assays has showed that women possess an increased platelet reactivity compared to their male counterparts, in terms of platelet-to-platelet aggregation [11][12][13][14], adhesiveness to fibrinogen [15][16][17][18][19][20] and interaction with leukocytes to form heterotypic aggregates [21]. In particular, some evidences have shown that platelet aggregation is enhanced in women.…”

Section: Gender Differences In Platelet Function and Clinical Implicamentioning

confidence: 99%

Gender differences in cardiovascular prophylaxis: Focus on antiplatelet treatment

Giosia

Passacquale

Petrarca

et al. 2017

Pharmacological Research

View full text Add to dashboard Cite

Cardiovascular disease (CVD) represents the leading cause of death worldwide, and equally affects both sexes although women develop disease at an older age than men. A number of clinical evidence has identified the female sex as an independent factor for poor prognosis, with the rate of mortality and disability following an acute cardiovascular (CV) event being higher in women than men. It has been argued that the different level of platelet reactivity between sexes may account for a different responsiveness to anti-platelet therapy, with consequent important implications on clinical outcomes. However, conclusive evidence supporting the concept of a gender-dependent effectiveness of platelet inhibitors are lacking. On the contrary, sex-related dissimilarities have been evidenced in cardiovascular patients in terms of age of presentation, comorbidities such as obesity, diabetes and renal disease, and a different pharmacological approach to and effectiveness in controlling classical cardiovascular risk factors such as hypertension, glucose profile and lipid dysmetabolism. All these factors could place women at an increased level of cardiovascular risk compared to men, and may concur to an enhanced pro-thrombogenic profile. The purpose of this manuscript is to provide an overview of gender-related differences in cardiovascular treatment, in order to highlight the need to improve the pharmacological prophylaxis adopted in women through a more accurate evaluation of the overall cardiovascular risk profile with consequent establishment of a more effective and targeted anti-thrombotic strategy which is not limited to the use of antiplatelet agents.

show abstract

Section: Gender Differences In Platelet Function and Clinical Implicamentioning

confidence: 99%

Gender differences in cardiovascular prophylaxis: Focus on antiplatelet treatment

Giosia

Passacquale

Petrarca

et al. 2017

Pharmacological Research

View full text Add to dashboard Cite

show abstract

“…To account for these effects, a number of human studies have been carried out on platelets and the coagulation system, comparing their activity in men and women (for example, Brakman et al, 1966;Johnson et al, 1975) and women taking oral contraceptives (for a review of the literature, see Poller, 1978), but the results have proved inconsistent. Whilst many studies have been carried out in humans, few have investigated sex and hormonal influences on platelet sensitivity and coagulation in other species.…”

Section: Introductionmentioning

confidence: 99%

Sex and hormonal influences on platelet sensitivity and coagulation in the rat

Emms

Lewis

1985

British J Pharmacology

View full text Add to dashboard Cite

Platelet sensitivity to adenosine di‐phosphate (ADP), thrombin, collagen, arachidonic acid and prostaglandin I2 (PGI2) and the activity of the coagulation system as measured by the activated partial thromboplastin time, prothrombin time, Russell's viper venom time and plasma fibrinogen have been examined in male and female rats, female rats during the oestrous cycle and female rats treated with oestrogen and a progestogen. Male rat platelets were less sensitive to thrombin and more sensitive to inhibition by PGI2 than those from females and fibrinogen levels in male rat plasma were approximately twice those seen in females. During the oestrous cycle, platelets were more sensitive to ADP and less sensitive to thrombin at dioestrus. Following 6 weeks treatment with 17 β‐oestradiol or ethynyl oestradiol, both platelet aggregation and release of granular ATP induced by collagen were significantly reduced. Platelet sensitivity to other agents, ADP, arachidonic acid, thrombin and PGI2 was, however, unchanged following oestrogen treatment. Activation of factor X by Russell's viper venom was accelerated in rats treated with ethynyl oestradiol, although this enhancement was not reflected in the overall clotting times.

show abstract

“…In the female rabbits maturation results in a decrease in platelet a2-adrenoceptor number and attenuation of a2-adrenoceptor mediated aggregation in platelets but no changes in kidney or brain a2-adrenoceptors (Mishra et al, 1985a), while in older male animals a decrease in number in brain but not spleen or platelets has been observed (Hamilton et al, 1986). In man, with increasing age, decreases in the responsiveness of vascular postsynaptic a2-adrenoceptors (Docherty & Hyland, 1985a), no change in presynaptic a2-adrenoceptor mediated responses (Docherty & Hyland, 1985a) but an increase in the aggregatory response of platelets to adrenaline (Johnson et al, 1975) have been reported.…”

mentioning

confidence: 99%